vs
Enact Holdings, Inc.（ACT）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是Enact Holdings, Inc.的1.7倍（$540.7M vs $312.7M），Enact Holdings, Inc.同比增速更快（3.6% vs -14.1%），过去两年Enact Holdings, Inc.的营收复合增速更高（3.6% vs -2.3%）
Enact Holdings, Inc.是美国领先的私人抵押贷款保险服务商，为银行、信用社等各类住宅抵押贷款机构提供风险缓释解决方案，帮助首付较低的购房者获得可负担的住房贷款，助力更多美国普通消费者实现安居需求。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
ACT vs ICUI — 直观对比
营收规模更大
ICUI
是对方的1.7倍
$312.7M
营收增速更快
ACT
高出17.8%
-14.1%
两年增速更快
ACT
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $312.7M | $540.7M |
| 净利润 | — | $-15.7M |
| 毛利率 | — | 37.5% |
| 营业利润率 | 71.3% | 1.0% |
| 净利率 | — | -2.9% |
| 营收同比 | 3.6% | -14.1% |
| 净利润同比 | — | 34.0% |
| 每股收益（稀释后） | $1.23 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACTICUI
| Q4 25 | $312.7M | $540.7M | ||
| Q3 25 | $311.5M | $537.0M | ||
| Q2 25 | $304.9M | $548.9M | ||
| Q1 25 | $306.8M | $604.7M | ||
| Q4 24 | $301.8M | $629.8M | ||
| Q3 24 | $309.6M | $589.1M | ||
| Q2 24 | $298.8M | $596.5M | ||
| Q1 24 | $291.6M | $566.7M |
净利润ACTICUI
| Q4 25 | — | $-15.7M | ||
| Q3 25 | — | $-3.4M | ||
| Q2 25 | — | $35.3M | ||
| Q1 25 | — | $-15.5M | ||
| Q4 24 | — | $-23.8M | ||
| Q3 24 | — | $-33.0M | ||
| Q2 24 | — | $-21.4M | ||
| Q1 24 | — | $-39.5M |
毛利率ACTICUI
| Q4 25 | — | 37.5% | ||
| Q3 25 | — | 37.4% | ||
| Q2 25 | — | 37.9% | ||
| Q1 25 | — | 34.7% | ||
| Q4 24 | — | 36.1% | ||
| Q3 24 | — | 34.8% | ||
| Q2 24 | — | 34.8% | ||
| Q1 24 | — | 32.7% |
营业利润率ACTICUI
| Q4 25 | 71.3% | 1.0% | ||
| Q3 25 | 67.4% | 2.6% | ||
| Q2 25 | 70.4% | 1.9% | ||
| Q1 25 | 68.9% | 2.1% | ||
| Q4 24 | 68.9% | 6.0% | ||
| Q3 24 | 74.1% | 1.4% | ||
| Q2 24 | 78.6% | 1.3% | ||
| Q1 24 | 70.6% | -1.9% |
净利率ACTICUI
| Q4 25 | — | -2.9% | ||
| Q3 25 | — | -0.6% | ||
| Q2 25 | — | 6.4% | ||
| Q1 25 | — | -2.6% | ||
| Q4 24 | — | -3.8% | ||
| Q3 24 | — | -5.6% | ||
| Q2 24 | — | -3.6% | ||
| Q1 24 | — | -7.0% |
每股收益（稀释后）ACTICUI
| Q4 25 | $1.23 | $-0.63 | ||
| Q3 25 | $1.10 | $-0.14 | ||
| Q2 25 | $1.11 | $1.43 | ||
| Q1 25 | $1.08 | $-0.63 | ||
| Q4 24 | $1.05 | $-0.97 | ||
| Q3 24 | $1.15 | $-1.35 | ||
| Q2 24 | $1.16 | $-0.88 | ||
| Q1 24 | $1.01 | $-1.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $582.5M | — |
| 总债务越低越好 | $744.5M | — |
| 股东权益账面价值 | $5.4B | $2.1B |
| 总资产 | $6.9B | $4.1B |
| 负债/权益比越低杠杆越低 | 0.14× | — |
8季度趋势，按日历期对齐
现金及短期投资ACTICUI
| Q4 25 | $582.5M | — | ||
| Q3 25 | $545.6M | — | ||
| Q2 25 | $616.0M | — | ||
| Q1 25 | $639.0M | — | ||
| Q4 24 | $602.8M | $308.6M | ||
| Q3 24 | $674.9M | $312.5M | ||
| Q2 24 | $711.3M | $302.6M | ||
| Q1 24 | $624.3M | $251.4M |
总债务ACTICUI
| Q4 25 | $744.5M | — | ||
| Q3 25 | $744.1M | — | ||
| Q2 25 | $743.8M | — | ||
| Q1 25 | $743.4M | — | ||
| Q4 24 | $743.0M | — | ||
| Q3 24 | $742.7M | — | ||
| Q2 24 | $742.4M | — | ||
| Q1 24 | $746.1M | — |
股东权益ACTICUI
| Q4 25 | $5.4B | $2.1B | ||
| Q3 25 | $5.3B | $2.1B | ||
| Q2 25 | $5.2B | $2.1B | ||
| Q1 25 | $5.1B | $2.0B | ||
| Q4 24 | $5.0B | $2.0B | ||
| Q3 24 | $5.0B | $2.0B | ||
| Q2 24 | $4.8B | $2.0B | ||
| Q1 24 | $4.7B | $2.1B |
总资产ACTICUI
| Q4 25 | $6.9B | $4.1B | ||
| Q3 25 | $6.9B | $4.1B | ||
| Q2 25 | $6.8B | $4.1B | ||
| Q1 25 | $6.7B | $4.2B | ||
| Q4 24 | $6.5B | $4.2B | ||
| Q3 24 | $6.6B | $4.3B | ||
| Q2 24 | $6.3B | $4.3B | ||
| Q1 24 | $6.3B | $4.3B |
负债/权益比ACTICUI
| Q4 25 | 0.14× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.14× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $724.5M | $60.6M |
| 自由现金流经营现金流 - 资本支出 | — | $36.0M |
| 自由现金流率自由现金流/营收 | — | 6.6% |
| 资本支出强度资本支出/营收 | — | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $91.8M |
8季度趋势，按日历期对齐
经营现金流ACTICUI
| Q4 25 | $724.5M | $60.6M | ||
| Q3 25 | $192.0M | $56.7M | ||
| Q2 25 | $119.5M | $11.2M | ||
| Q1 25 | $226.7M | $51.3M | ||
| Q4 24 | $686.3M | $40.2M | ||
| Q3 24 | $188.1M | $36.1M | ||
| Q2 24 | $144.7M | $82.0M | ||
| Q1 24 | $187.3M | $45.8M |
自由现金流ACTICUI
| Q4 25 | — | $36.0M | ||
| Q3 25 | — | $27.6M | ||
| Q2 25 | — | $-8.5M | ||
| Q1 25 | — | $36.7M | ||
| Q4 24 | — | $16.1M | ||
| Q3 24 | — | $16.2M | ||
| Q2 24 | — | $62.5M | ||
| Q1 24 | — | $29.9M |
自由现金流率ACTICUI
| Q4 25 | — | 6.6% | ||
| Q3 25 | — | 5.1% | ||
| Q2 25 | — | -1.5% | ||
| Q1 25 | — | 6.1% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 10.5% | ||
| Q1 24 | — | 5.3% |
资本支出强度ACTICUI
| Q4 25 | — | 4.6% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | — | 3.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 3.3% | ||
| Q1 24 | — | 2.8% |
现金转化率ACTICUI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.32× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACT
暂无分部数据
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
